MX2024009818A - Tratamiento de cancer. - Google Patents

Tratamiento de cancer.

Info

Publication number
MX2024009818A
MX2024009818A MX2024009818A MX2024009818A MX2024009818A MX 2024009818 A MX2024009818 A MX 2024009818A MX 2024009818 A MX2024009818 A MX 2024009818A MX 2024009818 A MX2024009818 A MX 2024009818A MX 2024009818 A MX2024009818 A MX 2024009818A
Authority
MX
Mexico
Prior art keywords
lag
subject
derivative
protein
administered
Prior art date
Application number
MX2024009818A
Other languages
English (en)
Spanish (es)
Inventor
Frédéric Triebel
Original Assignee
Immutep Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2201803.0A external-priority patent/GB202201803D0/en
Priority claimed from GBGB2218181.2A external-priority patent/GB202218181D0/en
Application filed by Immutep Sas filed Critical Immutep Sas
Publication of MX2024009818A publication Critical patent/MX2024009818A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2024009818A 2022-02-11 2023-02-10 Tratamiento de cancer. MX2024009818A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2201803.0A GB202201803D0 (en) 2022-02-11 2022-02-11 Treatment of Cancer
GBGB2218181.2A GB202218181D0 (en) 2022-12-02 2022-12-02 Treatment of cancer
PCT/EP2023/053381 WO2023152335A1 (en) 2022-02-11 2023-02-10 Treatment of cancer

Publications (1)

Publication Number Publication Date
MX2024009818A true MX2024009818A (es) 2024-08-19

Family

ID=85227021

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009818A MX2024009818A (es) 2022-02-11 2023-02-10 Tratamiento de cancer.

Country Status (9)

Country Link
US (1) US20250368714A1 (enExample)
EP (1) EP4475955A1 (enExample)
JP (1) JP2025505738A (enExample)
KR (1) KR20240149422A (enExample)
AU (1) AU2023219133A1 (enExample)
CA (1) CA3250299A1 (enExample)
IL (1) IL314687A (enExample)
MX (1) MX2024009818A (enExample)
WO (1) WO2023152335A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025229157A1 (en) * 2024-05-01 2025-11-06 Immutep S.A.S. Combination therapy using lag-3 protein and anti-pd-1 inhibitor with radiotherapy for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
EP4157313A1 (en) * 2020-05-28 2023-04-05 Immutep S.A.S. Treatment of cancer

Also Published As

Publication number Publication date
US20250368714A1 (en) 2025-12-04
IL314687A (en) 2024-10-01
EP4475955A1 (en) 2024-12-18
KR20240149422A (ko) 2024-10-14
CA3250299A1 (en) 2023-08-17
AU2023219133A1 (en) 2024-09-05
JP2025505738A (ja) 2025-02-28
WO2023152335A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
US6448287B1 (en) Treatment of cancer using lipoic acid in combination with ascorbic acid
Sobrinho et al. Amenorrhea in patients with Hodgkin's disease treated with antineoplastic agents
AU636489B2 (en) Tgf-beta compositions
Öberg et al. Cytotoxic treatment in patients with malignant carcinoid tumors: response to streptozocin—alone or in combination with 5-FU
Nadler et al. The effect of hypophysectomy on the experimental production of rat thyroid neoplasms
Manheimer et al. Mitomycin‐C in the therapy of far‐advanced malignant tumors
Moore et al. Adrenalectomy with chemotherapy in the treatment of advanced breast cancer: objective and subjective response rates; duration and quality of life
Adams et al. Inhibition of prostaglandin synthesis and leucocyte migration by flurbiprofen
Klijn et al. Anti-tumor and endocrine effects of chronic LHRH agonist treatment (buserelin) with or without tamoxifen in premenopausal metastatic breast cancer
BERGH et al. Menstrual function and serum prolactin levels after long‐term bromocriptine treatment of hyperprolactinaemic amenorrhoea
US3849562A (en) Method of treating nephrosis
Schomburg et al. Lack of therapeutic efficacy of tamoxifen in advanced renal cell carcinoma
Street et al. Cyclosporine in the treatment of cutaneous T cell lymphoma
Gordon et al. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
Kampmann et al. Acral erythema secondary to high‐dose cytosine arabinoside with pain worsened by cyclosporine infusions
Welsch et al. Comparative effects of hypophysectomy, ergocornine and ergocornine‐reserpine treatments on rat mammary carcinoma
Wittert et al. Arginine vasopressin in Cushing's disease
Moskovitz et al. Effect of Diclofenac Sodium (Voltaren) and Prostaglandin E (2) on Spermatogenesis in Mature Dogs
Tagiyev et al. Severe hypercalcemia in a child with acute lymphoblastic leukemia relapse: successful management with combination of calcitonin and bisphosphonate
NAGASAWA et al. Inhibition of pituitary prolactin secretion by human placental lactogen in rats
Malone et al. Combination interferon-α2a and 13-cis-retinoic acid enhances radiosensitization of human malignant glioma cells in vitro
Falkson et al. Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancer
JP2004529924A5 (enExample)
MX2022014909A (es) Tratamiento del cáncer.
US3105007A (en) Composition for the alleviation of pain in tumor growth